Full Professor of Otorhinolaryngology - Federal University of São Paulo (UNIFESP) - Paulista School of Medicine (EPM). Professor at the Professional Master's Degree Program in Body Balance Rehabilitation and Social Inclusion at the Bandeirante University of São Paulo.
Senior Associate Professor of Neurotology. Associate Professor - Otology and Neurotology Program - Federal University of São Paulo - Paulista School of Medicine.
Braz J Otorhinolaryngol. 2011 Jul-Aug;77(4):499-503. doi: 10.1590/S1808-86942011000400014.
Betahistine is a medicine used to treat vestibular disorders that has also been used to treat tinnitus.
To assess the effects of betahistine on tinnitus in patients with vestibular disorders.
Retrospective data were collected from patient records for individuals presenting with vestibular dysfunction and tinnitus. Patients included had received betahistine 48 mg/day and clinical outcomes were compared with a control group comprising individuals who were unable to receive betahistine due to gastritis, ulcers, pregnancy, asthma or hypersensitivity to the drug. Patients underwent control of any aggravating factors and also standard vestibular exercises as a basis for treatment. The intensity, frequency and duration of tinnitus were assessed on the first day of dosing and after 120 days of treatment. Clinical improvement was defined as a total or partial reduction of tinnitus after treatment.
Clinical improvement was observed in 80/262 (30. 5%) of patients treated with betahistine and 43/252 (17. 1%) of control patients. Betahistine significantly (p<0. 0001) improved tinnitus in treated individuals.
The daily dosage of 48 mg of betahistine during 120 consecutive days is useful to reduce or eliminate tinnitus in patients with vestibular disorders.
倍他司汀是一种用于治疗前庭障碍的药物，也已用于治疗耳鸣。
评估倍他司汀对前庭障碍患者耳鸣的影响。
从出现前庭功能障碍和耳鸣的患者的病历中收集回顾性数据。包括接受倍他司汀 48 毫克/天治疗的患者，并将其临床结果与因胃炎、溃疡、怀孕、哮喘或对药物过敏而无法接受倍他司汀的对照组进行比较。患者接受了任何加重因素的控制以及标准前庭运动作为治疗的基础。在开始治疗的第一天和治疗 120 天后评估耳鸣的强度、频率和持续时间。临床改善定义为治疗后耳鸣完全或部分减轻。
接受倍他司汀治疗的 262 例患者中有 80 例（30.5%）和对照组的 252 例患者中有 43 例（17.1%）观察到临床改善。倍他司汀显著（p<0.0001）改善了治疗患者的耳鸣。
连续 120 天每天服用 48 毫克的倍他司汀有助于减少或消除前庭障碍患者的耳鸣。
